First Eagle Investment Management
PLX icon

First Eagle Investment Management’s Protalix BioTherapeutics PLX Stock Holding History

First Eagle Investment Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-70,000
Closed -$2.72M – 403
2013
Q4 		$2.72M Buy
70,000
+20,000
+40% +$842K 0.01% 182
2013
Q3 		$2.27M Hold
50,000
– – 0.01% 198
2013
Q2 		$2.46M Buy
+50,000
New +$2.65M 0.01% 216

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

First Eagle Investment Management's PLX Position: Q1 2014 in Review

First Eagle Investment Management sold out of Protalix BioTherapeutics (PLX) in Q1 2014, closing a stake of 70,000 shares — an estimated $2.72M sold.

First Eagle Investment Management first reported a position in PLX in Q2 2013 and held it in 3 quarters. The position peaked at $2.72M in Q4 2013. 44 funds tracked by Wall St. Rank hold PLX as of Q1 2014.

  • First Eagle Investment Management reported no remaining Protalix BioTherapeutics position as of Q1 2014 after selling out during the quarter.
  • First Eagle Investment Management sold 70,000 Protalix BioTherapeutics shares in Q1 2014, an estimated $2.72M.
  • First Eagle Investment Management first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 3 quarters.
  • First Eagle Investment Management's Protalix BioTherapeutics position peaked at $2.72M in Q4 2013.
  • 44 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2014.

Based on First Eagle Investment Management's 13F filing for Q1 2014, filed 13 May 2014.